Skye Bioscience (SKYE) Net Cash Flow (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Net Cash Flow of $2.3 million for Q1 2026, up 110.3% year-over-year from $1.1 million in Q1 2025, and up 118.05% quarter-over-quarter from -$12.6 million in Q4 2025.
Skye Bioscience (SKYE) Net Cash Flow (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Net Cash Flow for 15 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 110.3% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at -$38.3 million (up 16.8% YoY), while the FY2025 annual figure was -$62.5 million, down 207.67% from the prior year.
- Net Cash Flow improved to $2.3 million in Q1 2026 per SKYE's latest filing, from -$12.6 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $82.1 million in Q1 2024 and bottomed at -$22.6 million in Q2 2025.
- Historically, Net Cash Flow has averaged -$49327.2 across 5 years, with a median of -$3.1 million in 2022.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 9174.48% — and 2024, when it soared 5663.79%.
- Skye Bioscience's Net Cash Flow stood at $829144.0 in 2022, then plunged by 567.28% to -$3.9 million in 2023, then slumped by 108.47% to -$8.1 million in 2024, then slumped by 55.48% to -$12.6 million in 2025, then surged by 118.05% to $2.3 million in 2026.
- Business Quant data shows SKYE's Net Cash Flow at $2.3 million in Q1 2026, -$12.6 million in Q4 2025, and -$5.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Skye Bioscience | 11.17 Mn | 11.17 Mn | - | -80,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.27 Mn |
| Mar 31, 2026 | 2.27 Mn |
| Dec 31, 2025 | -12.56 Mn |
| Dec 31, 2025 | -12.56 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Sep 30, 2025 | -5.40 Mn |
| Jun 30, 2025 | -22.58 Mn |
| Jun 30, 2025 | -22.58 Mn |
| Mar 31, 2025 | -21.99 Mn |
| Mar 31, 2025 | -21.99 Mn |
| Dec 31, 2024 | -8.08 Mn |
| Dec 31, 2024 | -8.08 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Sep 30, 2024 | -6.71 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Mar 31, 2024 | 82.09 Mn |
| Mar 31, 2024 | 82.09 Mn |
| Dec 31, 2023 | -3.87 Mn |
| Dec 31, 2023 | -3.87 Mn |